Start with it. Stay with it.®

Starting treatment with Adequan® i.m. (polysulfated glycosaminoglycan) at the early signs of arthritis can help slow the progression of cartilage deterioration in horses’ joints. Administer Adequan i.m. at the approved label dose (500 mg) according to the recommended 1 • 4 • 7 schedule to help achieve the improvement shown in studies.1,2

Dosing Example

Fast relief by the numbers

Once injected, peak levels of Adequan i.m. in the joints are achieved within two hours. Hyaluronic acid (HA) levels nearly double at 48 hours with significant increases noted from 24 up to 96 hours.2 Clinical significance of these results is unknown.

Peak levels achieved in the joints within

2 hours

HA nearly doubles at


The clinical significance of the results is unknown.4
Detected in cartilage and subchondral bone up to


After the initial series, you and the horse owner should continue monitoring joint health and mobility. You may repeat the 1 • 4 • 7 series as needed if the clinical signs of arthritis return.

Learn more about the science behind our dosing schedule in the Adequan i.m. Technical Bulletin and Prescribing Information on dosing.


Reduce lameness.
Improve carpal flexion1

In a dose response study, after the first four Adequan i.m. injections at the approved label dose (500 mg), the average improvement was 19%. After completing the seven-dose series at the approved label dose, the average improvement was 71% for a total of over 50% improvement in maximum carpal flexion.1

A placebo-controlled, blinded dose titration study was conducted in a total of 36 healthy, mature horses that were either Quarter Horses or Thoroughbreds. An induced adjuvant carpitis in the horse was used to assess the dose and efficacy of the intramuscular administration of Adequan i.m. The adjuvant induced arthritis was produced with a single intraarticular injection of 0.5 mL of Freunds adjuvant. The various treatments comprised sterile saline solution as a placebo control and 50 mg, 125 mg, 250 mg, 500 mg and 1,000 mg of the active drug substance Adequan i.m. dissolved in sterile water. Injections were given every 4 days for a total of 7 injections. Treatment followed a 10-day acclimation period and a 5-day model induction period.1

Doctor to doctor: When to re-treat

Watch to hear more detail from Avi Blake, DVM, a technical services veterinarian with American Regent Animal Health, on the dosing regimen, including how often to re-treat.


Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan (PSGAG). Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For full prescribing information, click here.

Resources to support your recommendation

Check out our library of resources for handy tools to facilitate your conversations with owners about their horse’s mobility.


Stay informed on Adequan i.m.

Be the first to hear about important news and product information.


  1. Adequan® i.m. (polysulfated glycosaminoglycan) NADA 141-038 FOI Summary, 1989.
  2. Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703.
  3. All horses improved and the % improvement was mean 19 percent at injection 4 and mean 71 percent at injection 7 for over 50 percent improvement